Immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine under different vaccination intervals

• Príomhchruthaitheoirí: Xiao-Juan Yu (Údar), Juan Li (Údar), Zhi-Jie Lin (Údar), Hui Zhao (Údar), Bi-Zhen Lin (Údar), You-Lin Qiao (Údar), Yue-Mei Hu (Údar), Li-Hui Wei (Údar), Rong-Cheng Li (Údar), Wei-Dan Huang (Údar), Ting Wu (Údar), Shou-Jie Huang (Údar), Chang-Gui Li (Údar), Hui-Rong Pan (Údar), Jun Zhang (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: Taylor & Francis Group, 2020-07-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

A new Escherichia coli-produced human papillomavirus (HPV)-16/18 vaccine has been shown to be safe and highly efficacious and was recently licensed in China. As a post hoc analysis of the phase III trial, this study aimed to assess the impact of vaccination time deviations on the specific antibody r...